Martin E. Judge Joins Anyo Labs Advisory Board

"I know what pharma looks for.."

Dr. Martin E. Judge recently joined Anyo labs as a shareholder and advisor to further boost the company’s access to knowledge of, and experience in, the pharma industry.

With 40+ years of research innovation, including work at New York University and at Novo Nordisk, where he devoted the last years of this time there to tech scouting and licensing, he brings immense knowledge and a cross functional expertise both from a scientific and business perspective. Dr. Judge was responsible for the early Novo Nordisk research on GLP1 inhibitors as potential anti-obesity therapeutics, and then in Business Development for in-licensing of technologies from biotech companies. He has first-hand experience as to what block busting science looks like.

Having been part of multi-million dollar licensing deals, he will be working with the Anyo team to partner their technology, and in its efforts to discover and develop the drugs of tomorrow.